ClinicalTrials.gg
CompletedNCT04072744FOOTUpdated Feb 2, 2023

Foot Oedema Observed Over Time Study

An observational study in Heart Failure and Edema Leg, sponsored by Heartfelt Technologies. Completed at 5 sites in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-02-02.

Sponsored by Heartfelt Technologies · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
31
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 482 studies in Heart Failure with a site in United Kingdom — 100 open to participants now, 127 under way, 18 of them phase 3. Heart Failure · United Kingdom.

Enrollment
147th of 166
31 · median 281
Started
2019
with 20 others
Observational
166 of 482
46 open now
Registered
295th of 482
by date

Among the 482 studies in Heart Failure with a site in United Kingdom, this one is the 147th largest by enrollment of the 166 observational ones that give a count, is one of 21 that started in 2019, is one of 166 observational ones, and was the 295th registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

100 of the 482 studies in Heart Failure with a site in United Kingdom are open now. Recruiting first, the newest first:

95 more — sign in →

All 100 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years and older · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 482 studies in Heart Failure with a site in United Kingdom, or all of them as a file.
02

Study summary

Heart Failure is the final common pathway of most forms of cardiovascular disease. In the United Kingdom (UK), it affects around 900 000 people, causes or complicates around 5% of adult emergency hospital admissions and consumes up to 2% of total National Health Service (NHS) expenditure. An important part of discharge planning includes measures such as early follow up in order to prevent readmissions. The hallmark of heart failure is fluid retention and between 2009 and 2016, 43% to 50% of hospital admissions were associated with peripheral oedema. Therefore, early recognition of this and treatment of the congestion may prevent hospital admissions. In clinical trials, management strategies have included patient education, telemedicine and remote monitoring. The main non-invasive method for detecting fluid retention has been the use of weight as a surrogate marker.

The Heartfelt device is an invention that uses a system of cameras in a compact device in order to generate 3 dimensional images of the feet and lower legs. The volumes can then be calculated and thus, changes in amount of peripheral oedema can be estimated. In a laboratory study performed by the Heart Failure team at the Royal Brompton Hospital, there was good correlation between measurements made by Heartfelt and a water displacement method. The resolution was as good as 20mls.

By positioning the Heartfelt device in the bedroom, automatic measurements can be made whenever the subject gets in and out of bed. Images are only taken of the specified subject. Data is censored so that the part of the body which is 50cm above the floor is not stored. Encrypted, anonymised data is transmitted over the internet to the company's secure servers. Personal identifiable data (participant name, address, age...) is stored on an encrypted hard drive, along with linkage information (device serial numbers) to associate the participant identifiable data with the data captured in the home. Therefore, data collection is not only secure but entirely passive, which is a major advantage compared with previous non-invasive methods and it is applicable to a very wide range of compliant and non-compliant patients.

Our hypothesis is that the Heartfelt device can directly detect the increase in peripheral oedema associated with heart failure decompensation and that, on average, the number of days with missing data collected by the Heartfelt device will be lower than that of the weighing scales.

Read the detailed description

This is a phase 2 observational study during which Subjects with chronic heart failure will be monitored in their home using the Heartfelt device.

The participant inclusion criteria will be those patients who are at high risk of hospital admission with a primary diagnosis of chronic heart failure or pulmonary oedema due to Heart failure (HF), during either of which peripheral oedema was also noted.

When heart failure decompensates, the amount of peripheral oedema that is clinically significant is unknown. The main objective of this study is to characterise the volume changes indicative of an increased risk for subsequent hospitalisation.

Subjects will also be provided with electronic, internet connected weighing scales that can transmit data and asked to weigh themselves daily. Temporal changes in weight and volume will be compared.

The study period will be 6 months and is the interval between installation of the Heartfelt device and the study end. participants will be made aware that the data collected by the device will not be reviewed during the study and therefore that they should continue with reporting symptoms and issues as usual to their care team.

In the event that it takes more than 2 years to recruit 20 participants, the study team will stop recruiting after 2 years so the study will be considered complete when all participants recruited up to that point have been monitored for 6 months.

participants under the care of the Trust have the following post diagnosis care:

  • Patient Education and Training in self management

    • Daily weighing
    • Diuretic management
  • Discharged under cardiologist
  • Home visit by heart failure nurse (HFN) at 7-10d
  • Urgent contact info for HF team
  • Subsequent HF care by

    • HFN either at home or at community hospital
    • Consultant cardiologist

The Heartfelt Device will be provided in addition to these and not replace any of these activities.

During the study period, data will be collected from the Heartfelt device (passively) and a set of connected weighing scales (as and when the participant steps on the scales). Any decisions made by the subject to seek medical help will not be influenced by the research team or the Heartfelt device readings as those would be concealed to the participant and research team until appropriate review during the study. The participant will however be able to see the readings on the weighing scales as they step on it.

Retrospective analysis of the participant's notes which may indicate change in medications or care will be mapped to the foot volumes and weights collected.

For those participants for whom decompensation occurs during the study period, the participants are seen by their healthcare professionals, and a clinical examination will be made as usual in a timely manner to determine the amount of peripheral oedema. This will be logged allowing retrospective comparison with the volume measurements.

The temporal relationship between volume changes and decompensation will be investigated. The additional effect of clinical status data will be assessed.

As the participation in a scientific study is known to modify behaviour, the information collected by scales and general reporting frequency of symptoms will be compared to the 6 months before the study and the 6 months after. The time to recruit participants should correct for any seasonal effect on this data.

03

Conditions studied

  • Heart Failure
  • Edema Leg

Keywords

  • Peripheral oedema
  • Peripheral edema
  • Heart failure
  • Decompensation
  • Weight
  • Hospital admissions
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Locally resident patients who are under the care of the cardiology / heart failure team with a high risk for heart failure related hospital admission, are potentially eligible.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients age 18 years or older.
  2. Patient able, agrees and signs the Form.
  3. Patient with any heart failure diagnosis.
  4. Patient under the care of a cardiologist with heart failure nurse care.
  5. Patient with one prolonged inpatient stay
  6. Patient with significant peripheral oedema at admission
  7. Patient with significant weight loss following admission (at least 5kg weight loss).
  8. Patient has been discharged on at least furosemide 80mg or Bumetanide 2mg/d

Exclusion criteria

Exclusion Criteria:

  1. Patient has bandages everyday
  2. Patient has an amputation of the foot
  3. Patient lacks capacity to consent
  4. Patient is of no fixed abode
  5. Patient has plans for intervention (CRT, Valves)
  6. Patient taking part in another study
  7. Patient must not been pregnant, and is taking relevant *

    • Note that criteria (g) has been requested by the insurance for clinical trial cover. However we do not expect participants of this study to be trying to get pregnant (participants are expected to be over 55 years old).
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
31 participants (actual)
Patient registry
No

Groups and cohorts

  • Participants

    General Study Participants

    Device: Heartfelt measurements · Device: Connected weighing scales

Interventions

  • DeviceHeartfelt measurements

    The measurements taken using the Heartfelt device do not require contact with the participant. For the measurements to take place, the participant will simply walk in the field of view of the device. As the device(s) will have been installed at a location allowing the best view of where the participant goes in an out of bed, the participant is not expected to change anything to their routine. The device can also take measurements in the dark, so if the participant walks in front of the device in the dark, this information will also be captured. The Heartfelt device is a CE (European Conformity) marked product. Neither the participant, or the medical team will be able to see the data collected by the Heartfelt device during the study. They will be blinded to the data until each participant has completed the study. At that point they can choose to review the data from participant individually or wait until all the data from all participants is available.

  • DeviceConnected weighing scales

    The participant will be instructed to use those scales for the period of the study, as often as directed by their healthcare professional. The weighing scales display weight so that the participants can record the weight in their own heart failure records. The participant will be able to see the weight readings on the weighing scales during the study. The scales will communicate with the Personal Computer (PC) contained in the Heartfelt device and the data will be sent to the Heartfelt server through an encrypted link.

06

What researchers measure

Primary outcomes

  1. Change in foot volume prior to Heart failure related hospital admission

    The primary outcome is the change in foot volume between baseline and the last observed foot volume measurement prior to hospital admission for a given patient. This will aim to demonstrate the ability of the heartfelt system to provide advance warning of impending hospitalisation.

    Time frame: Through study completion, an average of 6 months

Secondary outcomes

  1. Frequency of data collection by the Heartfelt Device

    the frequency with which the heartfelt system collects patient data in comparison to standard care (weighing scales).

    Time frame: Through study completion, an average of 6 months

  2. Correlation between foot volume and significant medical intervention

    The correlation between the dates of significant medical interventions (change of diuretics, hospital admission...) and difference in foot volumes to baseline measured by the Heartfelt device.

    Time frame: Through study completion, an average of 6 months

07

Study locations

5 sites
  • Bedfordshire Hospitals NHS Foundation Trust
    Luton, Bedfordshire LU4 0DZ, United Kingdom
  • North Tees and Hartlepool Hospitals NHS Foundation Trust
    Stockton-on-Tees, County Durham TS19 8PE, United Kingdom
  • Torbay and South Devon NHS Foundation Trust
    Torquay, Devon TQ27AA, United Kingdom
  • University Hospitals of Leicester NHS Trust
    Leicester, Leicestershire LE3 9QP, United Kingdom
  • Northumbria Healthcare NHS Foundation Trust
    North Shields, Northumbria NE29 8NH, United Kingdom
08

References and documents

Individual participant data

Plan to share: No — No identifiable data will be shared with other researchers

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2019 to primary completion in Dec 2022, 36 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 23, 2019
First posted
Aug 28, 2019
StartActual
Dec 11, 2019
Primary completionActual
Dec 30, 2022
CompletionActual
Dec 30, 2022
Last update
Feb 2, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 2, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04072744
Lead sponsor
Heartfelt Technologies
Collaborators
Torbay and South Devon NHS Foundation Trust
Responsible party
Sponsor
First posted
Aug 28, 2019
Start date
Dec 11, 2019
Primary completion
Dec 30, 2022
Completion
Dec 30, 2022
Last update
Feb 2, 2023

Study contacts

Phil Keeling, MD
principal investigator · Torbay and South Devon NHS Foundation Trust

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion